“LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT”. Mediterranean Journal of Hematology and Infectious Diseases, vol. 16, no. 1, Apr. 2024, p. e2024039, https://doi.org/10.4084/MJHID.2024.039.